NK Cells and CD1d-restricted NKT Cells Respond in Different Ways with Divergent Kinetics to IL-2 Treatment in Primary HIV-1 Infection

Scandinavian Journal of Immunology

Volumn 73, Issue 2, 2011, Pages 141-146

  Kuylenstierna, C ^a   Snyder Cappione, J E ^b   Loo, C P ^b   Long, B R ^b   Gonzalez, V D ^a   Michaelsson J ^a   Moll, M ^a   Spotts, G ^b   Hecht, F M ^c   Nixon, D F ^b   Sandberg, J K ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD1D ANTIGEN; CD56 ANTIGEN; GALACTOSYLCERAMIDE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1BETA;

ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; DENDRITIC CELL; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOTHERAPY; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; NATURAL KILLER T CELL; PHENOTYPE; PRIORITY JOURNAL;

ANTIGENS, CD1D; DENDRITIC CELLS; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; KILLER CELLS, NATURAL; KINETICS; NATURAL KILLER T-CELLS;

EID: 78650787660     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2010.02484.x     Document Type: Article

References (24)

1. Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004;114:1379-88.
2. Diana J, Lehuen A. NKT cells: friend or foe during viral infections? Eur J Immunol 2009;39:3283-91.
3. Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol 2010;11:197-206.
4. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 2002;195:625-36.
5. Sandberg JK, Fast NM, Palacios EH et al. Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection. J Virol 2002;76:7528-34.
6. Vasan S, Tsuji M. A double-edged sword: the role of NKT cells in malaria and HIV infection and immunity. Semin Immunol 2010;22:87-96.
7. Yang OO, Wilson SB, Hultin LE et al. Delayed reconstitution of CD4+ iNKT cells after effective HIV type 1 therapy. AIDS Res Hum Retroviruses 2007;23:913-22.
8. Motsinger A, Haas DW, Stanic AK, Van Kaer L, Joyce S, Unutmaz D. CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. J Exp Med 2002;195:869-79.
9. Moll M, Kuylenstierna C, Gonzalez VD et al. Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection. Eur J Immunol 2009;39:902-11.
10. Snyder-Cappione JE, Loo CP, Carvalho KI et al. Lower cytokine secretion ex vivo by natural killer T cells in HIV-infected individuals is associated with higher CD161 expression. AIDS 2009;23:1965-70.
11. Moll M, Andersson SK, Smed-Sorensen A, Sandberg JK. Inhibition of lipid antigen presentation in dendritic cells by HIV-1 Vpu interference with CD1d recycling from endosomal compartments. Blood 2010;116:1876-84.
12. Alter G, Altfeld M. NK cell function in HIV-1 infection. Curr Mol Med 2006;6:621-9.
13. Gonzalez VD, Landay AL, Sandberg JK. Innate immunity and chronic immune activation in HCV/HIV-1 co-infection. Clin Immunol 2010;135:12-25.
14. Fauci AS, Mavilio D, Kottilil S. NK cells in HIV infection: paradigm for protection or targets for ambush. Nat Rev Immunol 2005;5:835-43.
15. De Maria A, Fogli M, Costa P et al. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol 2003;33:2410-8.
16. Mavilio D, Benjamin J, Daucher M et al. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A 2003;100:15011-6.
17. Eller MA, Eller LA, Ouma BJ et al. Elevated natural killer cell activity despite altered functional and phenotypic profile in Ugandans with HIV-1 clade A or clade D infection. J Acquir Immune Defic Syndr 2009;51:380-9.
18. Bjorkstrom NK, Ljunggren HG, Sandberg JK. CD56(neg) NK cells: origin, function, and role in chronic viral disease. Trends Immunol 2010;31:401-6.
19. Tarazona R, Casado JG, Delarosa O et al. Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals. J Clin Immunol 2002;22:176-83.
20. Moll M, Snyder-Cappione J, Spotts G, Hecht FM, Sandberg JK, Nixon DF. Expansion of CD1d-restricted NKT cells in patients with primary HIV-1 infection treated with interleukin-2. Blood 2006;107:3081-3.
21. Michaelsson J, Long BR, Loo CP et al. Immune reconstitution of CD56(dim) NK cells in individuals with primary HIV-1 infection treated with interleukin-2. J Infect Dis 2008;197:117-25.
22. Abrams D, Levy Y, Losso MH et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009;361:1548-59.
23. Tavel JA, Babiker A, Fox L et al. Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study. PLoS ONE 2010;5:e9334.
24. Hecht FM, Busch MP, Rawal B et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 2002;16:1119-29.